OTCMKTS:RCDTF Recordati Industria Chimica e Farmaceutica (RCDTF) Stock Price, News & Analysis $55.54 0.00 (0.00%) As of 03/13/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest About Recordati Industria Chimica e Farmaceutica Stock (OTCMKTS:RCDTF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RCDTF alerts:Sign Up Key Stats Today's Range$55.54▼$55.5450-Day Range$55.54▼$55.5452-Week Range$52.25▼$52.25Volume5 shsAverage Volume9 shsMarket Capitalization$11.46 billionP/E Ratio27.77Dividend YieldN/APrice TargetN/AConsensus RatingReduce Company OverviewRecordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.Read More… Remove Ads Receive RCDTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recordati Industria Chimica e Farmaceutica and its competitors with MarketBeat's FREE daily newsletter. Email Address RCDTF Stock News Headlines3 European Stocks Estimated To Be Undervalued In March 2025March 3, 2025 | finance.yahoo.comRecordati Industria Chimica e Farmaceutica SPA (0KBS) Receives a Hold from Kepler CapitalFebruary 21, 2025 | markets.businessinsider.comEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… They’re studying something far more alien… Something you’ve never seen before…March 14, 2025 | Paradigm Press (Ad)Recordati stock falls on stake sale newsFebruary 19, 2025 | in.investing.comRecordati stock rating cut to sell by Deutsche BankFebruary 7, 2025 | msn.comRecordati downgraded to Sell from Hold at Deutsche BankFebruary 7, 2025 | markets.businessinsider.comRecordati Industria Chimica e Farmaceutica S.p.A. (0KBS.IL)February 4, 2025 | ca.finance.yahoo.comRecordati and its top investor say no plans for deal with AngeliniJanuary 17, 2025 | msn.comSee More Headlines RCDTF Stock Analysis - Frequently Asked Questions How have RCDTF shares performed this year? Recordati Industria Chimica e Farmaceutica's stock was trading at $55.54 at the beginning of the year. Since then, RCDTF shares have increased by 0.0% and is now trading at $55.54. View the best growth stocks for 2025 here. How do I buy shares of Recordati Industria Chimica e Farmaceutica? Shares of RCDTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today3/14/2025Next Earnings (Estimated)3/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:RCDTF Previous SymbolNASDAQ:RCDTF CIKN/A Webwww.recordati.com Phone390-248-7871Fax39-02-4007-3747Employees4,455Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$2.00 Trailing P/E Ratio27.77 Forward P/E RatioN/A P/E GrowthN/ANet Income$421.25 million Net Margins17.41% Pretax MarginN/A Return on Equity30.78% Return on Assets12.65% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.25 billion Price / Sales5.08 Cash Flow$3.06 per share Price / Cash Flow18.15 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares206,300,000Free FloatN/AMarket Cap$11.46 billion OptionableNot Optionable Beta0.30 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:RCDTF) was last updated on 3/14/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s new tariffs could break China’s grip on manufacturingLooming trade wars have China scrambling… Over 90% of global corporate executives said they are shutting do...Weiss Ratings | SponsoredIs 2025 really the best time to get rich in American history?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump's 100-Day Plan Triggers Global RetaliationIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recordati Industria Chimica e Farmaceutica S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recordati Industria Chimica e Farmaceutica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.